BiotechTube

Sacituzumab tirumotecan

Phase 2Recruiting
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Phase II

Conditions

Phase II, Sacituzumab, Tirumotecan, SMARCB1-deficient Renal Medullary Carcinoma

Trial Timeline

Jun 1, 2026 → Feb 1, 2030

NCT ID
NCT07438626

About Sacituzumab tirumotecan

Sacituzumab tirumotecan is a phase 2 stage product being developed by Merck for Phase II. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07438626. Target conditions include Phase II, Sacituzumab, Tirumotecan.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT07438626Phase 2Recruiting
NCT07458113Phase 2Recruiting

Competing Products

20 competing products in Phase II

See all competitors
ProductCompanyStageHype Score
TERN-701Terns PharmaceuticalsPhase 1/2
38
Tamsulosin HCl + Solifenacin Succinate + EC905Astellas PharmaPhase 1
33
solifenacin succinate + mirabegron + mirabegron/solifenacin succinateAstellas PharmaPhase 1
33
Graceptor®Astellas PharmaPre-clinical
23
Lemborexant + PlaceboEisaiApproved
85
BIW-8962Kyowa KirinPhase 1/2
41
AcalabrutinibAstraZenecaPhase 1/2
41
progesterone + ProgesteroneMerckApproved
85
AsciminibNovartisPre-clinical
23
NilotinibNovartisPhase 3
77
Imatinib mesylateNovartisPhase 3
77
Imatinib Mesylate 600 MG Oral Tablet + Imatinib Mesylate 400 MG Oral Tablet + Imatinib MesylateNovartisPhase 3
77
ribociclib + TrametinibNovartisPhase 1
33
NilotinibNovartisApproved
85
ImatinibNovartisPhase 3
77
NilotinibNovartisApproved
85
GleevecNovartisPhase 2
52
Nilotinib + RuxolitinibNovartisPhase 1/2
41
ABL001NovartisPhase 3
77
asciminibNovartisPhase 2
52

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85